Les biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer en pratique clinique courante [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].
Details
Serval ID
serval:BIB_EF61DD096D14
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Les biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer en pratique clinique courante [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].
Journal
Revue Medicale Suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
04/2016
Peer-reviewed
Oui
Volume
12
Number
515
Pages
791-794
Language
french
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Abstract
The cerebrospinal fluid levels of amyloid beta 1-42 (Aβ1-42), total tau and tau phosphorylated at threonine 181 (ptau181) are well established biomarkers of cerebral amyloid pathology and tau related neurodegeneration, two hallmarks of Alzheimer's disease. These biomarkers can help to improve diagnostic accuracy and consequent decisions on counseling, support, and therapy of patients with mild cognitive impairment and dementia. The use of biomarkers is part of the proposed new criteria of AD diagnosis. It may be particularly helpful in cases of atypical clinical presentation and uncertain diagnosis, and if an important benefit for the patient is expected. The ongoing development of new biomarkers based on less or non-invasive procedures will allow for a larger use of biomarkers to improve the diagnosis of cognitive impairment.
Keywords
Alzheimer Disease/cerebrospinal fluid, Alzheimer Disease/diagnosis, Amyloid beta-Peptides/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Cognitive Therapy/methods, Diagnosis, Differential, Early Diagnosis, Humans, Predictive Value of Tests, Sensitivity and Specificity, tau Proteins/cerebrospinal fluid
Pubmed
Create date
20/04/2016 17:44
Last modification date
20/08/2019 17:17